Literature DB >> 16643854

Expression of D2 dopamine receptor in the mouse brain.

Manjusha Rani1, M S Kanungo.   

Abstract

The neurotransmitter, dopamine, binds to dopamine receptor (DR), and is involved in several functions of the brain, such as initiation and execution of movement, emotion, prolactin secretion, etc. Of all the five DRs, D2 dopamine receptor has maximal affinity for dopamine. D2 has a short isoform, D2S, and a long isoform D2L. D2L is longer than D2S by 29 amino acid residues. We studied the expression of the gene and protein of D2 receptor in the cerebral and cerebellar cortices of the brain of new born, developing, adult, and old male mice to find out: (i) at what stage of development, expression of the gene peaks and (ii) if it undergoes any changes as the animal ages, which may account for the neurodegenerative changes and symptoms of Parkinson's and other diseases seen in old age. RT-PCR and Western blot studies show that peak expression of D2 gene occurs in the cerebral and cerebellar cortices around 15-day after birth. We speculate that the majority of dopaminergic synapses are established and possibly become functional in the brain around 15-day after birth. The expression of D2 receptor is upregulated in the cerebral cortex in old mice. However, it is down-regulated in the cerebellar cortex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16643854     DOI: 10.1016/j.bbrc.2006.03.075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Developmental changes in human dopamine neurotransmission: cortical receptors and terminators.

Authors:  Debora A Rothmond; Cynthia S Weickert; Maree J Webster
Journal:  BMC Neurosci       Date:  2012-02-15       Impact factor: 3.288

2.  Alteration of the Dopamine Receptors' Expression in the Cerebellum of the Lysosomal Acid Phosphatase 2 Mutant (Naked-Ataxia (NAX)) Mouse.

Authors:  Mehdi Mehdizadeh; Niloufar Ashtari; Xiaodan Jiao; Maryam Rahimi Balaei; Asghar Marzban; Farshid Qiyami-Hour; Jiming Kong; Saeid Ghavami; Hassan Marzban
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

3.  The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT- and rTg(P301L)4510 mouse models of Alzheimer's disease.

Authors:  Heidy Jimenez; Leslie Adrien; Adam Wolin; John Eun; Eric H Chang; Ethan S Burstein; Jesus Gomar; Peter Davies; Jeremy Koppel
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.